Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial

Lupus Erythematosus ◽

Subgroup Analysis ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Phase 3

Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial

Modern Rheumatology ◽

10.1080/14397595.2019.1630897 ◽

2019 ◽

Vol 30 (2) ◽

pp. 313-320 ◽

Cited By ~ 1

Author(s):

Yoshiya Tanaka ◽

Damon Bass ◽

Myron Chu ◽

Sally Egginton ◽

Beulah Ji ◽

...

Keyword(s):

Lupus Erythematosus ◽

Subgroup Analysis ◽

Controlled Trial ◽

Japanese Patients ◽

Organ System ◽

Systemic Lupus ◽

Phase 3

Faculty Opinions recommendation of Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.8909956.9465054 ◽

2011 ◽

Author(s):

David Kluth ◽

Neeraj Dhaun

Keyword(s):

Lupus Erythematosus ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Phase 3

EMBRACE: Phase 3/4, Randomized, 52‐Week Study of Belimumab Efficacy and Safety in Patients of Black African Ancestry With Systemic Lupus Erythematosus

Arthritis & Rheumatology ◽

10.1002/art.41900 ◽

2021 ◽

Author(s):

Ellen Ginzler ◽

Luiz Sergio Guedes Barbosa ◽

David D’Cruz ◽

Richard Furie ◽

Kathleen Maksimowicz‐McKinnon ◽

...

Keyword(s):

Lupus Erythematosus ◽

African Ancestry ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Phase 3 ◽

Black African

OP0184 Efficacy and Safety of Tabalumab in Patients with Systemic Lupus Erythematosus (SLE): Results from 2 Phase 3, 52-Week, Multicenter, Randomized, Placebo-Controlled Trials: Table 1

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2015-eular.1195 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 141.1-141 ◽

Cited By ~ 6

Author(s):

D. Isenberg ◽

J. Merrill ◽

R. Hoffman ◽

M. Linnik ◽

M. Morgan-Cox ◽

...

Keyword(s):

Lupus Erythematosus ◽

Controlled Trials ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Phase 3

O25 Efficacy of anifrolumab in active systemic lupus erythematosus (SLE): patient subgroup analysis of BICLA response in 2 phase 3 trials

10.1136/lupus-2020-eurolupus.36 ◽

2020 ◽

Author(s):

Eric F Morand ◽

Richard Furie ◽

Yoshiya Tanaka ◽

Rubana N Kalyani ◽

Gabriel Abreu ◽

...

Keyword(s):

Lupus Erythematosus ◽

Subgroup Analysis ◽

Systemic Lupus ◽

Phase 3 ◽

Patient Subgroup

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Yearbook of Medicine ◽

10.1016/j.ymed.2011.09.006 ◽

2011 ◽

Vol 2011 ◽

pp. 18-19

Author(s):

R.S. Panush

Keyword(s):

Lupus Erythematosus ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Phase 3

Effect of raloxifene on disease activity and vascular biomarkers in patients with systemic lupus erythematosus: Subgroup analysis of a double-blind randomized controlled trial

Lupus ◽

10.1177/0961203313507987 ◽

2013 ◽

Vol 22 (14) ◽

pp. 1470-1478 ◽

Cited By ~ 9

Author(s):

CC Mok ◽

Shirley KY Ying ◽

KM Ma ◽

CK Wong

Keyword(s):

Randomized Controlled Trial ◽

Disease Activity ◽

Lupus Erythematosus ◽

Subgroup Analysis ◽

Controlled Trial ◽

Systemic Lupus ◽

Double Blind ◽

Randomized Controlled ◽

Vascular Biomarkers

Faculty Opinions recommendation of Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.736643913.793576811 ◽

2020 ◽

Author(s):

Tak Mao Chan ◽

Susan Yung

Keyword(s):

Lupus Erythematosus ◽

Low Dose ◽

Controlled Trial ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo

Efficacy and safety of tabalumab plus standard of care in Japanese patients with active systemic lupus erythematosus: Subgroup analyses of the ILLUMINATE-1 study

Modern Rheumatology ◽

10.1080/14397595.2016.1206260 ◽

2016 ◽

Vol 27 (2) ◽

pp. 284-291 ◽

Cited By ~ 5

Author(s):

Yoshiya Tanaka ◽

Tsutomu Takeuchi ◽

Naotsugu Akashi ◽

Yasushi Takita ◽

Birgit Kovacs ◽

...

Keyword(s):

Lupus Erythematosus ◽

Standard Of Care ◽

Japanese Patients ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Subgroup Analyses

Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy

Modern Rheumatology ◽

10.3109/14397595.2015.1060665 ◽

2015 ◽

Vol 26 (1) ◽

pp. 80-86 ◽

Cited By ~ 17

Author(s):

Yoshiya Tanaka ◽

Tsutomu Takeuchi ◽

Nobuyuki Miyasaka ◽

Takayuki Sumida ◽

Tsuneyo Mimori ◽

...

Keyword(s):

Lupus Nephritis ◽

Lupus Erythematosus ◽

Conventional Therapy ◽

Japanese Patients ◽

Efficacy And Safety ◽

Systemic Lupus